Subscribe to RSS
Acquired Factor V Inhibitor after Coronavirus Disease 2019 (COVID-19)
Inhibitors directed against factor V (FV) occur seldom, primarily in the elderly, and the clinical presentation varies from asymptomatic laboratory abnormalities to life-threatening bleedings.  Acquired FV inhibitors usually are immunoglobulin of the G class (IgG) directed to the binding site for phosphatidylserine (present in the second C-type domain of the light chain of FV). Infections, drugs, surgical procedures, blood transfusions, solid and hematological cancers, and autoimmune disorders are associated with the risk of developing acquired FV inhibitors.  According to the specific targeted epitope (i.e., domains of light chain or heavy chain of FV), anti-FV antibodies affect the balance between pro- and anticoagulant functions of FV.  No definitive treatment strategy has been established. In approximately 50% of cases, the inhibitor is eliminated spontaneously.  
A 62-year-old Caucasian woman presented to the Hematology Department because of recurrent episodes of hematuria from 1 week, and bleeding from the sites of venous sampling. Coagulation tests showed that the platelet count was normal ([Table 1]): prolonged prothrombin time (PT): 45.5 seconds, international normalized ratio: 4.09, and activated partial thromboplastin time (aPTT): 165 seconds, aPTT ratio: 5.5. Coagulation factor II (FII), factor X (FX), factor VIII (FVIII), and fibrinogen were normal. The FV activity was 0.1% (range of normality 60–120%). The PT, aPTT, and one-stage coagulation factors assays were performed using an ACL TOP 550 coagulometer, and factor V was determined using a one-stage PT-based assay (using Recombiplastin 2G, Instrumental Laboratory Spa), and factor V-deficient substrate plasma (HemosIl, Instrumental Laboratory Spa). Anti-cardiolipin antibodies were negative. Mixing test of patient's plasma with normal pooled plasma revealed the existence of an FV inhibitor, with an activity level of 4.0 Bethesda unit/mL (Nijmegen modification of the Bethesda method) ([Table 1]). Two weeks before, the patient had been treated for coronavirus disease 2019 (COVID-19) at home, with steroids (dexamethasone 6 mg daily for 5 days), enoxaparin 4,000 IU daily, and oxygen. The clinical history of the patient included type 2 diabetes mellitus and arterial hypertension. At the time of diagnosis of FV inhibitor, antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG were positive: 140 AU/mL (positive >25). Antinuclear antibodies were negative and C-reactive protein was <0.33 (range of normality: 0–0.5). To eradicate the inhibitor, the patient was treated with dexamethasone 7.5 mg daily. Hematuria stopped soon after beginning treatment with dexamethasone, and the abnormalities in PT and aPTT improved and normalized in about 2 weeks ([Table 1]). Presently the patient is clinically well and is monitored on an outpatient basis with periodic coagulation tests.
Abbreviations: APTT, activated partial thromboplastin time; BU, Bethesda Units; FV, factor V; INR, international normalized ratio.
Previous reports have shown that acquired FV inhibitors are associated with transient mild bleeding episodes, and they frequently disappear in less than a month. This resembles the findings of our patient which is the second reported case of acquired FV inhibitor following COVID-19. Severe anemia, left psoas muscle hematoma, and left retroperitoneal cavity hematoma with FV activity <1% and FV inhibitor titer of 31.6 Bethesda unit/mL were reported in the first case in a patient with SARS-CoV-2 RNA testing positivity of the nasopharynx 2 weeks before presentation and for the following 4 weeks. The patient reported by Bennett et al did not respond to intravenous immunoglobulin and dexamethasone. Three cycles of plasma-exchange with fresh frozen plasma replacement resulted in the correction of bleeding and laboratory coagulopathy in that report.
The incidence of acquired FV inhibitors is extremely low, with a rate of 0.023 to 0.09 per million persons per year. The presence of both prolonged PT and aPTT (not corrected after mixing with normal plasma), and an isolated FV deficiency, in a patient with a negative personal/familial bleeding history, leads to the initial diagnosis of acquired FV inhibitor. The inhibitor is confirmed and titrated using the Bethesda method.   Some patients with acquired FV inhibitors present with abnormal clinical laboratory tests but have no hemorrhagic symptoms. Others experience life-threatening bleedings. Mucosal (i.e., gastrointestinal, genitourinary, airways) bleedings account for more than 60% of the clinical manifestations. Hematuria, often severe, complicated the clinical phenotype in approximately half of the cases. Thrombosis can also occur, when the inhibitors interfere with the cofactor activity of FV for activated protein C. In rare cases a lupus-anticoagulant-like activity was also demonstrated. 
Data regarding the management of acquired FV inhibitor are mostly based on case reports. Treatment includes hemostatic and immunosuppressive therapy. Corticosteroids or IVIG, and transfusion support in patients with severe bleeding are the most used treatments.  Some reports have shown that the administration of rituximab, cyclophosphamide, and plasma-exchange can be used.  However, no definitive treatment strategy has been established, and, in approximately 50% of cases, the inhibitor is eliminated spontaneously.
Coagulation abnormalities, thrombosis, and endothelial dysfunction are commonplace in patients with COVID-19, with higher incidence in severe cases, and the severity of alterations of coagulation parameters has been clearly associated with unfavorable prognosis. Thromboses are frequent in patients with severe COVID-19, while bleeding tendency in these patients is uncommon, and described as possible consequence of imbalances in platelet production/disruption, coagulation disorders, and antithrombotic prophylaxis.     This second case of acquired FV deficiency should be added to the already reported cases of acquired factor VIII deficiency (acquired hemophilia A)  in this infection and argue for an improvement in coagulation monitoring in patients with COVID-19 and otherwise unexplained hemorrhagic picture and/or abnormal prolongation of coagulation tests (PT and/or aPTT). However, we would like to emphasize that a causal relationship in our and other published cases is unproven, and that coincident findings of acquired inhibitors and COVID-19 are possible, as indeed are coincident findings of acquired inhibitors and COVID-19 vaccination.
F.C. and A.T. were responsible for conceiving the idea. A.T. wrote the manuscript and did the literature search. G.D.M. was responsible for critical revision of the manuscript. All the authors contributed to the approval of final manuscript.
24 September 2021 (online)
© 2021. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 1 Franchini M, Lippi G. Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis 2011; 31 (04) 449-457
- 2 Goulenok T, Vasco C, Faille D. et al; RAVI study group. Acquired factor V inhibitor: a nation-wide study of 38 patients. Br J Haematol 2021; 192 (05) 892-899
- 3 Yamada S, Asakura H. Acquired factor V inhibitor. Rinsho Ketsueki 2020; 61 (07) 791-798
- 4 Emori Y, Sakugawa M, Niiya K. et al. Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. Blood Coagul Fibrinolysis 2002; 13 (06) 555-559
- 5 Matsumoto T, Nogami K, Shima M. Coagulation function and mechanisms in various clinical phenotypes of patients with acquired factor V inhibitors. J Thromb Haemost 2014; 12 (09) 1503-1512
- 6 Bennett J, Cunningham MT, Howard C, Hoffmann M, Plapp FV. Acquired factor V inhibitor in the setting of coronavirus disease 2019 infection. Blood Coagul Fibrinolysis 2021; 32 (04) 294-297
- 7 Franchini M, Targher G, Montagnana M, Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta 2008; 395 (1-2): 14-18
- 8 Ortel TL. Clinical and laboratory manifestations of anti-factor V antibodies. J Lab Clin Med 1999; 133 (04) 326-334
- 9 Favaloro EJ, Bonar R, Duncan E. et al; RCPA QAP in Haematology Haemostasis Committee. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost 2006; 96 (01) 73-78
- 10 Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost 2020; 18 (09) 2103-2109
- 11 Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev 2021; 47: 100761
- 12 Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020; 7 (06) e438-e440
- 13 Marietta M, Coluccio V, Luppi M. COVID-19, coagulopathy and venous thromboembolism: more questions than answers. Intern Emerg Med 2020; 15 (08) 1375-1387
- 14 Lippi G, Sanchis-Gomar F, Favaloro EJ, Lavie CJ, Henry BM. Coronavirus disease 2019-associated coagulopathy. Mayo Clin Proc 2021; 96 (01) 203-217
- 15 Olsen GM, Rinder HM, Tormey CA. De novo acquired hemophilia as an immune dysregulation phenomenon following SARS-CoV-2 infection. Transfusion 2021; 61 (03) 989-991
- 16 Franchini M, Glingani C, De Donno G. et al. The first case of acquired hemophilia A associated with SARS-CoV-2 infection. Am J Hematol 2020; 95 (08) E197-E198
- 17 Cittone MG, Battegay R, Condoluci A. et al. The statistical risk of diagnosing coincidental acquired hemophilia A following anti-SARS-CoV-2 vaccination. J Thromb Haemost 2021; (e-pub ahead of print) DOI: 10.1111/jth.15421.